Minimize Risk of TRAEs (Transfusion Related Adverse Events)

Optimized integration of plasma by pooling 630 to 1,520 single units of FFP1
  • Minimizes risk of pathogen transmission1-4
    • Immune neutralization of enveloped and non-enveloped viruses
  • Minimizes risk of allergic reactions3
    • Dilution of substances that can lead to an allergic reaction
  • Minimizes risk of TRALI3
    • Dilution and neutralization of free anti-HLA/HNA antibodies
Cell and cell debris removal by filtration (1.0 µm)3
  • Minimizes risk of allergic reactions3
    • Removal of cell debris and cells such as mast cells, which contain histamine
  • Minimizes risk of TRALI3
    • Removal of cell-bound anti-HLA/HNA antibodies
    • Removal of bioactive lipids that are located on outer side of cells
S/D treatment
  • Minimizes risk of pathogen transmission2-4
    • Inactivation of enveloped viruses
Sterile filtration (0.2 μm)3
  • Minimizes risk of bacteria and parasite transmission5

TRALI = Transfusion-Related Acute Lung Injury, HLA = Human Leukocyte Antigen, HNA = Human Neutrophil Antigen.

icon-clip-board Created with Sketch.

Octaplas provides standardized concentrations of coagulation factors and inhibitors for bag-to-bag consistency.

Read More
References:
  1. Octapharma. Data on file; 2013.
  2. Octaplas, Pooled Plasma (Human), Solvent/Detergent Treated Solution for Intravenous Infusion, complete prescribing information. 2019.
  3. Bertolini J, Goss N, Curling J, eds. Production of Plasma Proteins for Therapeutic Use. Hoboken, NJ: John Wiley & Sons; 2013:345-351.
  4. Hellstern P, Solheim BG. The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother. 2011;38:65-70.
  5. WHO Technical Report, Series No. 924, 2004, Annex 4, Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products.